To the Editor We were interested by the recent article from Dr Mansi and colleagues who reported a significant progression of type 2 diabetes after initiation of statin therapy compared with initiation of proton pump inhibitor or H2-blocker.1 In their discussion, the authors acknowledged that the composite outcome for diabetes progression (ie, therapy escalation, persistent hyperglycemia >200 mg/dL, etc) was a study limitation; indeed data regarding hemoglobin A1C (HbA1c) levels were not collected. Although research shows that HbA1c levels increase marginally after initiating a statin (+0.1%),2 the difference may not be negligible when drug exposure is prolonged for years in patients with diabetes of long duration.
Rigalleau V, Mohammedi K, Foussard N. Strengthening a Study of Diabetes Progression After Statins Use. JAMA Intern Med. 2022;182(4):458–459. doi:10.1001/jamainternmed.2021.8350
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.